Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small synthetic compound derived from angiotensin IV, part of the renin-angiotensin system that is more traditionally associated with blood pressure regulation. Dihexa was developed by researchers at Washington State University who identified that certain fragments of the angiotensin pathway had effects on brain cells that were separate from their cardiovascular role. Unlike most peptides discussed in tissue-repair or performance research, Dihexa's primary research interest lies in neuroscience — specifically in the study of synaptic connectivity and cognitive function pathways.

​

Description

Dihexa is technically not a peptide in the traditional sense but is often grouped with peptide research compounds due to its peptide-derived structure and its method of study alongside other amino-acid-based research molecules. It is a small molecule with peptide-like properties, orally bioavailable in preclinical models (a distinguishing feature compared to most peptides, which typically require injection due to poor gut stability), and capable of crossing the blood-brain barrier — a property central to its research relevance.

​

Mechanism of Research Interest

Dihexa's proposed mechanism centers on its interaction with the hepatocyte growth factor (HGF)/c-Met receptor system in the brain. This pathway plays a role in:

• Synaptogenesis — the formation of new connections (synapses) between neurons

• Neuronal plasticity — the brain's capacity to reorganize and adapt neural pathways

• Dendritic spine density — structural features of neurons associated with memory and learning capacity

​​

Preclinical research has focused on Dihexa's potency relative to other compounds studied in the same synaptogenic pathway, with some early studies suggesting activity at very low concentrations compared to earlier angiotensin IV-related compounds studied for similar purposes.

​

Research Focus Areas

• Cognitive function and memory-related pathways (preclinical/animal models)

• Neurodegenerative research contexts (early-stage academic interest, not clinical treatment)

• Synaptic plasticity and neural connectivity studies

• Blood-brain barrier permeability research as a delivery model of interest

• Comparative pharmacology within the angiotensin IV/HGF research pathway

​​

Distinguishing Characteristics

• Oral bioavailability in preclinical study models, distinguishing it from most injectable research peptides

• CNS (central nervous system) penetration, a rare property among peptide-class research compounds

• Structurally classified as a "peptide-derived small molecule" rather than a conventional peptide chain

​​

Status

Dihexa remains an early-stage academic and preclinical research compound. It has not progressed through human clinical trials in a way that supports any claims of safety, efficacy, or therapeutic use. It is not approved by the FDA or any regulatory authority for any use in humans or animals, and is intended strictly for laboratory research purposes.